GlassScriptPhysician profile
Kevin B Fox
NPI 1477510311
$2,279.20
in general payments reported to CMS, 2019-2025
29 companies · $72.60 in 2025
The $72.60 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $126 · 2021: $345 · 2022: $504 · 2023: $382 · 2024: $457 · 2025: $72.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $911.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $356.15 | 2022-2025 | Mako, Triathlon |
| Abbvie INC. | $271.86 | 2021-2024 | |
| Zimmer Biomet Holdings, INC. | $224.81 | 2019 | |
| Lilly USA, LLC | $195.24 | 2020-2024 | Mounjaro, Jardiance |
| Abbott Laboratories | $190.95 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Astrazeneca Pharmaceuticals LP | $139.51 | 2021-2024 | Airsupra |
| Promius Pharma LLC | $136.65 | 2019 | |
| Exact Sciences Corporation | $107.79 | 2023-2024 | Cologuard Collection Kit |
| Medtronic, INC. | $101.21 | 2024 | Synchromedii, Intellis Adaptivestim |
| Pfizer INC. | $71.63 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $56.39 | 2021-2023 | |
| Amgen INC. | $49.95 | 2022-2023 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $48.80 | 2022 | |
| Allergan, INC. | $44.32 | 2020 | |
| Phadia US INC. | $41.75 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $37.70 | 2022-2024 | |
| Glaxosmithkline, LLC. | $22.44 | 2023 | Shingrix, Arexvy |
| Horizon Therapeutics Plc | $19.72 | 2019 | |
| Astellas Pharma US INC | $18.28 | 2023 | Veozah |
| Fidia Pharma USA INC. | $18.06 | 2025 | Triluron, Hymovis |
| Hologic Sales and Service, LLC | $17.70 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.53 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.88 | 2023 | Quviviq |
| Alvogen INC | $16.76 | 2023 | Teriparatide |
| Neurelis, INC. | $16.45 | 2023 | Valtoco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.02 | 2021 | |
| Novo Nordisk INC | $13.37 | 2021 | |
| Cranial Technologies, INC | $12.28 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.